-
Safety data demonstrates the biosimilarity
-
No Difference in Median LVEF between OGIVRI and reference trastuzumab
-
No new safety signals in long-term follow up*
For US Healthcare Professionals Only
Connect with us for news and updates related to OGIVRI® (trastuzumab-dkst) injection.
*All fields required